Peptide delivery of a multivalent mRNA SARS-CoV-2 vaccine.
Envelope antigen
Intradermal
Membrane antigen
Peptide
RALA
SARS-CoV-2
Spike antigen
Vaccine
mRNA
Journal
Journal of controlled release : official journal of the Controlled Release Society
ISSN: 1873-4995
Titre abrégé: J Control Release
Pays: Netherlands
ID NLM: 8607908
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
03
05
2023
revised:
06
08
2023
accepted:
27
08
2023
pubmed:
31
8
2023
medline:
31
8
2023
entrez:
30
8
2023
Statut:
ppublish
Résumé
Lipid nanoparticles (LNP) have been instrumental in the success of mRNA vaccines and have opened up the field to a new wave of therapeutics. However, what is ahead beyond the LNP? The approach herein used a nanoparticle containing a blend of Spike, Membrane and Envelope antigens complexed for the first time with the RALA peptide (RALA-SME). The physicochemical characteristics and functionality of RALA-SME were assessed. With >99% encapsulation, RALA-SME was administered via intradermal injection in vivo, and all three antigen-specific IgG antibodies were highly significant. The IgG2a:IgG1 ratio were all >1.2, indicating a robust T
Identifiants
pubmed: 37648082
pii: S0168-3659(23)00553-9
doi: 10.1016/j.jconrel.2023.08.053
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
536-547Informations de copyright
Copyright © 2023 The Authors. Published by Elsevier B.V. All rights reserved.